Zollinger‑Ellison Gastrinoma (Benign) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Gastrinoma (Benign) – Complete Guide

Zollinger‑Ellison Gastrinoma (Benign) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison gastrinoma is a rare neuroendocrine tumor that originates in the pancreas or duodenum and secretes excessive amounts of gastrin, a hormone that stimulates the stomach to produce acid. The resulting hyperacidity can lead to severe peptic ulcers, diarrhea, and malabsorption. When the tumor is confined to the lining of the organ and shows no evidence of invasion or metastasis, it is classified as benign. However, even benign gastrinomas can cause significant morbidity if left untreated.

Who it affects: Most patients are adults between 30‑60 years old; men and women are affected equally. Approximately 70 % of gastrinomas are associated with the genetic condition Zollinger‑Ellison Syndrome (ZES), which may be part of the hereditary Multiple Endocrine Neoplasia type 1 (MEN‑1) syndrome.

Prevalence: Gastrinomas are estimated to occur in 1‑3 per million people worldwide. Of these, roughly 20‑30 % are benign at the time of diagnosis, while the remainder show local invasion or metastasis, most commonly to the liver or regional lymph nodes (NIH, 2022).[1]

Symptoms

Symptoms stem from the excess gastric acid and from the tumor itself. Not every patient experiences all of them, and severity can vary.

Gastro‑intestinal symptoms

  • Abdominal pain – usually a burning or gnawing sensation in the upper abdomen, often worsened by meals.
  • Peptic ulcers – multiple, large, or refractory ulcers in the stomach, duodenum, or even the jejunum.
  • Diarrhea – watery, sometimes greasy stools caused by acid‑induced inactivation of pancreatic enzymes.
  • Acid reflux / heartburn – chronic gastro‑esophageal reflux disease (GERD) due to high acid volume.
  • Nausea & vomiting – especially after large meals.

Systemic symptoms

  • Weight loss – from malabsorption and decreased appetite.
  • Fatigue – secondary to anemia from chronic bleeding or nutrient deficiencies.
  • Steatorrhea – fatty stools when acid damage impairs fat digestion.

Signs related to the tumor itself

  • Palpable abdominal mass – rare, often only detectable with imaging.
  • Elevated serum gastrin – >1000 pg/mL in most cases (normal < 100 pg/mL).

Causes and Risk Factors

Primary cause

Zollinger‑Ellison gastrinoma arises from the uncontrolled growth of gastrin‑producing G‑cells. The majority are sporadic, but 25‑30 % occur in the context of inherited MEN‑1 syndrome, caused by mutations in the MEN1 tumor suppressor gene.[2]

Risk factors

  • Genetic predisposition – family history of MEN‑1 or ZES.
  • Age – risk rises after the third decade of life.
  • Chronic Helicobacter pylori infection – may exacerbate ulcer formation but is not a direct cause of gastrinomas.
  • Smoking – linked to neuroendocrine tumor development in several studies.

Diagnosis

Because the disease is rare and symptoms overlap with common ulcer disease, a systematic approach is essential.

Step‑wise diagnostic work‑up

  1. Clinical suspicion – persistent, refractory ulcer disease, especially with multiple ulcers or ulcer recurrence after standard therapy.
  2. Serum gastrin measurement – drawn after an overnight fast; levels >1000 pg/mL are highly suggestive. If gastrin is modestly elevated (100‑1000 pg/mL), a secretin stimulation test is performed: gastrin should rise >120 pg/mL after IV secretin in ZES.
  3. Imaging – to locate the tumor:
    • Contrast‑enhanced CT or MRI of the abdomen (sensitivity 70‑80 %).
    • Somatostatin receptor scintigraphy (Octreoscan) or newer Ga‑68 DOTATATE PET/CT (>90 % detection rate).
    • Endoscopic ultrasound (EUS) – useful for small pancreatic lesions.
  4. Endoscopy – upper GI endoscopy confirms ulcer number, size, and location; biopsies rule out malignancy.
  5. Genetic testing – recommended for patients with a family history of MEN‑1 or ZES, or those diagnosed before age 30.

Key diagnostic criteria for a benign gastrinoma

  • Elevated fasting gastrin (>1000 pg/mL) with a positive secretin test.
  • Imaging that shows a solitary, well‑circumscribed lesion without regional lymph node enlargement or distant metastasis.
  • Histopathology (if resected) showing low mitotic index, Ki‑67 < 3 % (WHO grade 1).

Treatment Options

Treatment aims to control acid hypersecretion, eradicate the tumor when feasible, and prevent complications.

1. Acid‑suppression therapy (first line)

  • Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are the cornerstone. Typical dosing: 60‑120 mg daily, divided doses, titrated to symptom control.[3]
  • H2-receptor antagonists – cimetidine or ranitidine (if PPIs are contraindicated), but they are less effective for ZES.

2. Surgical management

Curative resection is preferred for localized benign gastrinomas.

  • Enucleation – removal of the tumor alone, suitable for small (<2 cm) lesions away from major ducts.
  • Partial pancreatectomy or duodenectomy – indicated when the tumor is larger or situated near the pancreatic head.
  • Minimally invasive (laparoscopic) approaches are increasingly common, offering shorter hospital stays.

Post‑operative cure rates exceed 80 % for truly benign, solitary lesions (NIH, 2022).[1]

3. Medical therapy for unresectable or metastatic disease (not typical for benign cases)

  • Somatostatin analogues (octreotide, lanreotide) – suppress gastrin release.
  • Targeted therapy – everolimus or sunitinib for advanced neuroendocrine tumors.

4. Lifestyle and supportive measures

  • Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
  • Limit alcohol and caffeine, which increase gastric acid.
  • Eat small, frequent meals; avoid foods that trigger reflux.
  • Maintain adequate calcium and vitamin D intake; chronic PPI use can reduce absorption.

Living with Zollinger‑Ellison Gastrinoma (Benign)

Medication adherence

Take PPIs exactly as prescribed—missing doses can lead to breakthrough ulcers and pain. Keep a medication log or use a smartphone reminder.

Monitoring

  • Follow‑up labs – fasting gastrin every 6‑12 months after surgery or when symptoms change.
  • Imaging surveillance – CT or MRI annually for the first 3 years, then every 2‑3 years if stable.
  • Endoscopic checks – upper endoscopy every 1‑2 years to ensure ulcer healing.

Nutrition

Because high acid can impair nutrient absorption, consider:

  • High‑protein, low‑fat diet until digestion normalizes.
  • Supplemental pancreatic enzymes if steatorrhea persists.
  • Vitamin B12, iron, calcium, and magnesium supplementation after discussion with your physician.

Quality of life

Engage in regular, low‑impact exercise (walking, yoga) to reduce stress, which can worsen acid secretion. Join support groups for rare endocrine tumors – many organizations (e.g., NEA) offer online forums.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, you can reduce overall risk and mitigate disease impact:

  • Genetic counseling – families with MEN‑1 should undergo testing and regular surveillance.
  • Smoking cessation – lowers neuroendocrine tumor risk.
  • Prompt treatment of H. pylori – eliminates a co‑factor for ulcer disease.
  • Avoid chronic use of ulcer‑inducing medications unless medically necessary.

Complications

If untreated or poorly controlled, a benign gastrinoma can lead to serious health problems:

  • Peptic ulcer perforation – life‑threatening abdominal emergency.
  • Upper gastrointestinal bleeding – melena or hematemesis requiring transfusion.
  • Severe malabsorption – leading to weight loss, anemia, osteoporosis.
  • Gastric outlet obstruction – from scarring or tumor growth.
  • Progression to malignancy – while rare (<5 % of benign gastrinomas), long‑standing disease can evolve into a malignant neuroendocrine tumor.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain with a rigid or board‑like abdomen (possible ulcer perforation).
  • Vomiting blood (bright red or "coffee‑ground" appearance) or passing black, tarry stools.
  • Rapid heart rate, fainting, or a sudden drop in blood pressure.
  • Persistent, profuse diarrhea leading to dehydration (dry mouth, dizziness, reduced urine output).
  • Unexplained high fever (>38.5 °C / 101.3 °F) combined with abdominal pain.

Sources: [1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022. https://www.niddk.nih.gov.
[2] Mayo Clinic. “Multiple Endocrine Neoplasia Type 1 (MEN1).” 2023. https://www.mayoclinic.org.
[3] American College of Gastroenterology Clinical Guideline: Management of Acid‑Related Diseases. 2021. https://gi.org.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References